从腕带到植入物:可穿戴设备在心力衰竭护理中的变革性作用
Catarina Gregório1,2,3,4, João R Agostinho1,2,3,4, Joana Rigueira1,2,3,4
1Department of Cardiology, Hospital de Santa Maria (ULSSM), 1649-028 Lisbon, Portugal.
Healthcare (Basel, Switzerland)
|January 8, 2025
概括
可穿戴设备为心力衰竭 (HF) 管理提供了有前途的解决方案,通过实现连续远程监测和早期检测脱补偿. 整合这些技术可以个性化护理并改善患者的治疗结果,尽管仍然存在挑战.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 数字健康数字健康
背景情况:
- 心力衰竭 (HF) 管理需要创新的解决方案,以加强监测和个性化护理.
- 最初用于健身的可穿戴设备,在HF患者的临床决策中显示出潜力.
- 本研究探讨了可穿戴技术的集成,用于远程监控和个性化高频护理.
研究的目的:
- 评估可穿戴技术在心力衰竭管理中的作用和潜力.
- 探索诸如生命体征跟踪,患者参与和临床决策支持等功能.
- 分析临床结果和与HF护理中可穿戴设备采用相关的障碍.
主要方法:
- 进行了全面的文献审查.
- 审查的重点是可穿戴功能,临床结果和采用障碍.
- 对高频管理中的可穿戴设备现有研究进行批判性分析.
主要成果:
- 可穿戴设备可以跟踪关键的HF参数 (心率,活动,睡眠) 并检测心律失常.
- 它们有助于早期诊断,患者风险分层和生活方式修改促进.
- 可穿戴设备可以评估液体状况,预防住院治疗,并优化心脏康复.
- 可以进行持续的非侵入性监测,但存在数据整合和监管障碍.
结论:
- 可穿戴技术可以通过持续监测和早期干预来彻底改变高频管理.
- 合作对于克服整合挑战和临床验证可穿戴设备至关重要.
- 广泛采用需要解决数据整合,监管和退款障碍.
更多相关视频
相关概念视频
Pulse rhythm
758
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
758
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Holter Monitor: 24-Hour Monitoring
1
Holter monitoring is a continuous electrocardiography (ECG) recording that tracks the heart's electrical activity over an extended period, generally 24 to 48 hours. This noninvasive diagnostic tool detects irregular heart rhythms that may not be captured during a standard ECG performed in a clinical setting.DeviceThe Holter monitor is a portable, small device connected to several electrodes on the patient's chest. These electrodes detect the heart's electrical signals and transmit them to the...
1
Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381


